Anti-CTLA-4 (CD 152) monoclonal antibody-induced autoimmune interstitial nephritis

Elaine C Jolly; Menna R Clatworthy; Christopher Lawrence; Paul D Nathan; Ken Farrington

doi:10.1093/ndtplus/sfp048

Anti-CTLA-4 (CD 152) monoclonal antibody-induced autoimmune interstitial nephritis

Elaine C Jolly, Menna R Clatworthy, Christopher Lawrence, Paul D Nathan, Ken Farrington

Research output: Contribution to journal › Article › peer-review

6 Citations (Scopus)

10 Downloads (Pure)

Abstract

Targeted immune-modulating agents are entering clinical practice in many specialties, providing novel therapeutic possibilities but introducing new potential toxicities. We present the first reported case, to our knowledge, of immune-mediated nephritis following the administration of Tremelimumab (CP-675, 206), an anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) monoclonal antibody. High-dose steroid therapy led to a rapid improvement in renal function, avoiding the need for renal replacement therapy.

Original language	English
Pages (from-to)	300-2
Number of pages	3
Journal	NDT Plus
Volume	2
Issue number	4
DOIs	https://doi.org/10.1093/ndtplus/sfp048
Publication status	Published - 28 Apr 2009

Keywords

Journal Article

Access to Document

10.1093/ndtplus/sfp048Licence: CC BY

sfp048Final published version, 341 KBLicence: CC BY

Cite this

@article{256d63f2969941f2b8daeb215ef7b177,

title = "Anti-CTLA-4 (CD 152) monoclonal antibody-induced autoimmune interstitial nephritis",

abstract = "Targeted immune-modulating agents are entering clinical practice in many specialties, providing novel therapeutic possibilities but introducing new potential toxicities. We present the first reported case, to our knowledge, of immune-mediated nephritis following the administration of Tremelimumab (CP-675, 206), an anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) monoclonal antibody. High-dose steroid therapy led to a rapid improvement in renal function, avoiding the need for renal replacement therapy.",

keywords = "Journal Article",

author = "Jolly, {Elaine C} and Clatworthy, {Menna R} and Christopher Lawrence and Nathan, {Paul D} and Ken Farrington",

year = "2009",

month = apr,

day = "28",

doi = "10.1093/ndtplus/sfp048",

language = "English",

volume = "2",

pages = "300--2",

journal = "NDT Plus",

issn = "1753-0784",

publisher = "Oxford University Press (OUP)",

number = "4",

}

TY - JOUR

T1 - Anti-CTLA-4 (CD 152) monoclonal antibody-induced autoimmune interstitial nephritis

AU - Jolly, Elaine C

AU - Clatworthy, Menna R

AU - Lawrence, Christopher

AU - Nathan, Paul D

AU - Farrington, Ken

PY - 2009/4/28

Y1 - 2009/4/28

N2 - Targeted immune-modulating agents are entering clinical practice in many specialties, providing novel therapeutic possibilities but introducing new potential toxicities. We present the first reported case, to our knowledge, of immune-mediated nephritis following the administration of Tremelimumab (CP-675, 206), an anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) monoclonal antibody. High-dose steroid therapy led to a rapid improvement in renal function, avoiding the need for renal replacement therapy.

AB - Targeted immune-modulating agents are entering clinical practice in many specialties, providing novel therapeutic possibilities but introducing new potential toxicities. We present the first reported case, to our knowledge, of immune-mediated nephritis following the administration of Tremelimumab (CP-675, 206), an anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) monoclonal antibody. High-dose steroid therapy led to a rapid improvement in renal function, avoiding the need for renal replacement therapy.

KW - Journal Article

U2 - 10.1093/ndtplus/sfp048

DO - 10.1093/ndtplus/sfp048

M3 - Article

C2 - 25984021

SN - 1753-0784

VL - 2

SP - 300

EP - 302

JO - NDT Plus

JF - NDT Plus

IS - 4

ER -

Anti-CTLA-4 (CD 152) monoclonal antibody-induced autoimmune interstitial nephritis

Abstract

Keywords

Access to Document

Fingerprint

Cite this